Who makes XS003 under fed and fasted condition?

XS003 under fed and fasted condition is developed by Xspray Pharma AB.

What development phase is XS003 under fed and fasted condition in?

XS003 under fed and fasted condition is in Phase 1.

Last reviewed 2026-05-13 · How we verify

XS003 under fed and fasted condition

Xspray Pharma AB · Phase 1 active Small molecule

At a glance

Generic name	XS003 under fed and fasted condition
Sponsor	Xspray Pharma AB
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Bioavailability Study of XS003 (Nilotinib) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XS003 under fed and fasted condition CI brief — competitive landscape report
XS003 under fed and fasted condition updates RSS · CI watch RSS
Xspray Pharma AB portfolio CI